Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

Inclusion Criteria:

• Participants with documented histopathological diagnosis of locally advanced ormetastatic CRC, who were intolerant/refractory to or progressed after standardsystemic therapies for the advanced/metastatic stage that included and arerestricted to a fluoropyrimidine, irinotecan, a platinum agent (e.g. oxaliplatin),an anti-EGFR agent (if clinically indicated, i.e. RAS/BRAF wt), and an anti-VEGFagent. Participants may have received previous treatment with trifluridine/tipiraciland/or regorafenib or fruquintinib, if locally indicated and available. Participantswith a known MSI-H status must have received treatment with an immune checkpointinhibitor (if locally indicated and available) unless contraindicated

• Eastern Cooperative Oncology Group Performance Status (ECOG PS) below or equal to 1

• Participants with adequate hematologic, hepatic and renal function as defined inprotocol

• Other protocol defined inclusion criteria could apply

Exclusion Criteria:

• Participant has a history of malignancy within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situof the cervix, benign prostate neoplasm/hypertropia, or malignancy that in theopinion of the Investigator, with concurrence with the Sponsor's Medical Monitor, isconsidered cured with minimal risk of recurrence within 3 years)

• Participants with known brain metastases, except those meeting the followingcriteria: Brain metastases that have been treated locally and are clinically stablefor at least 4 weeks prior to the start of treatment; No ongoing neurologicalsymptoms that are related to the brain localization of the disease (sequelae thatare a consequence of the treatment of the brain metastases are acceptable)

• Participants with diarrhea (liquid stool) or ileus Grade > 1

• Cerebrovascular accident/stroke (< 6 months prior to enrollment)

• Other protocol defined exclusion criteria could apply